Foghorn therapeutics provides update on fhd-286 clinical development program and strategic priorities

Objective clinical responses by standard response criteria observed in phase 1 dose escalation trial for fhd-286 in combination with decitabine in patients with relapsed and/or refractory aml; efficacy threshold not achieved to support continued development by foghorn alone

FHTX Ratings Summary

FHTX Quant Ranking